The Electronic Identification and Trust Services for Electronic Transactions Regulations 2016

National Health Service (Pharmaceutical and Local Pharmaceutical Services) Regulations 2013 U.K.

9.  In regulation 2(1) (interpretation) of the National Health Service (Pharmaceutical and Local Pharmaceutical Services) Regulations 2013 M1 —

(a) for the definition of “advanced electronic signature”, substitute—

““advanced electronic signature” means an electronic signature which meets the following requirements—

(a) it is uniquely linked to the signatory;

(b) it is capable of identifying the signatory;

(c) it is created using electronic signature creation data that the signatory can, with a high level of confidence, use under the signatory's sole control; and

(d) it is linked to the data signed in such a way that any subsequent change in the data is detectable;”;

(b) after the definition “electronic repeatable prescription”, insert—

““electronic signature” means data in electronic form which is attached to or logically associated with other data in electronic form and which is used by the signatory to sign;

“electronic signature creation data” means unique data which is used by the signatory to create an electronic signature;”; and

(c) after the definition “scheme premises” insert—

““signatory” means a natural person who creates an electronic signature;”.

Marginal Citations

M1 S.I. 2013/349, to which there are amendments not relevant to these Regulations.